Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Tipo de estudo
Intervalo de ano de publicação
1.
PLoS One ; 19(3): e0287390, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38507417

RESUMO

OBJECTIVE: To determine the effective dose and therapeutic potential of maropitant using through expression of mediators of oxidative stress, inflammatory and of the unfolded protein response (UPR) (bio) markers on spinal cord using a model of neuropathic pain induced through chronic constriction injury (CCI) in rats. STUDY DESIGN: Randomized, blinded, prospective experimental study. ANIMALS: 98 male Wistar rats. METHODS: Rats were anesthetized with sevoflurane and after CCI, they were randomly assigned to the following groups that received: vehicle, 3, 6, 15, 30 e 50 mg/kg/24q of maropitant. The effect on inflammatory mediators (IL10, TNFα), oxidative stress (GPx, CAT, SOD), microglial (IBA-1) and neuronal (NeuN, TACR1) markers was evaluated though immunohistochemistry and expression levels of markers of hypoxia (HIF1α, Nrf2), antioxidant enzymes (Catalse, Sod1 and GPx1), and endoplasmic reticulum stress mediators (GRP78, CHOP and PERK) through qRT-PCR. RESULTS: Intraperitoneal injection (IP) of maropitant inhibited nociception with ID50 values of 4,1 mg/kg (5,85-19,36) in a neuropathic pain model through CCI. A dose of 30 mg/kg/24q was significantly effective in reducing mechanical allodynia 1 to 4h after treatment with nociception inhibition (145,83%). A reduction in the expression of hypoxia factors (HIF1α, Nrf2) was observed, along with an increase in antioxidant activity (CAT, SOD and GPX). Additionally, there was a reduction in inflammatory markes (IL10, TNFα), microglial (IBA-1), and neuronal markers (NeuN, TACR1). CONCLUSION AND CLINICAL RELEVANCE: These findings demonstrate that the determined dose, administered daily for seven days, had an antinociceptive effect, as well as anti-inflammatory and antioxidant activity.


Assuntos
Neuralgia , Traumatismos dos Nervos Periféricos , Quinuclidinas , Ratos , Masculino , Animais , Antioxidantes/metabolismo , Ratos Wistar , Doenças Neuroinflamatórias , Traumatismos dos Nervos Periféricos/tratamento farmacológico , Fator de Necrose Tumoral alfa/metabolismo , Interleucina-10/metabolismo , Fator 2 Relacionado a NF-E2/metabolismo , Estudos Prospectivos , Estresse Oxidativo , Hiperalgesia/tratamento farmacológico , Estresse do Retículo Endoplasmático , Neuralgia/tratamento farmacológico , Neuralgia/metabolismo , Superóxido Dismutase/metabolismo , Hipóxia/tratamento farmacológico
2.
J Vet Med Sci ; 81(6): 946-948, 2019 Jun 28.
Artigo em Inglês | MEDLINE | ID: mdl-30996203

RESUMO

Mesothelioma is a very aggressive malignant tumor with low survival rates that is often diagnosed belatedly. Pericardial effusion is a common consequence in cases of mesothelioma, with pericardiocentesis and pericardiectomy indicated; therefor thoracocentesis is necessary to drain the contents no longer retained in the pericardium. The present report describes a mesothelioma-carrying dog with a history of cardiac tamponade that underwent thoracoscopic pericardiectomy and, later, thoracoscopic implantation of a fully implantable catheter to function as a thoracic drain. In the consulted literature, there is no use of a fully implantable catheter for this purpose. The authors consider that there was an improvement in the quality of life.


Assuntos
Doenças do Cão/cirurgia , Neoplasias Pulmonares/cirurgia , Mesotelioma/cirurgia , Pericardiectomia/veterinária , Toracoscopia/veterinária , Animais , Cateteres de Demora/veterinária , Cães , Feminino , Mesotelioma Maligno , Derrame Pericárdico/cirurgia , Derrame Pericárdico/veterinária , Pericardiectomia/métodos , Toracoscopia/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...